{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The proportion of patients who discontinued the study due to Zydelig-related adverse events.","groups":[{"description":"Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.\n\nZydelig: Zydelig given at 150mg continuously in 28-day cycles","id":"OG000","title":"Oral Zydelig 150 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year.","title":"Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year","type":"PRIMARY","unitOfMeasure":"Participants"}